What are the recommended treatment regimens for uncomplicated urogenital, rectal, or pharyngeal Chlamydia trachomatis infection in non‑pregnant adults and adolescents, and the alternatives for pregnant patients and neonates?

Treatment Guidelines for Chlamydia

For uncomplicated urogenital, rectal, or pharyngeal chlamydia in non-pregnant adults, treat with either azithromycin 1 g orally as a single dose or doxycycline 100 mg orally twice daily for 7 days—both achieve 97-98% cure rates and are equally effective first-line options. 1, 2

First-Line Treatment Selection

Azithromycin 1 g Single Dose

• Preferred when compliance is uncertain because it enables directly observed therapy in the clinic, eliminating the risk of incomplete treatment 1, 3
• Achieves approximately 97% microbial cure rate 1, 2
• Particularly useful in populations with erratic health-care-seeking behavior or unpredictable follow-up 1
• Can be dispensed on-site with the first dose observed to maximize adherence 1

Doxycycline 100 mg Twice Daily for 7 Days

• Preferred when cost is a primary concern due to lower expense and extensive clinical experience 1, 3
• Achieves approximately 98% microbial cure rate 1, 2
• Superior efficacy for rectal chlamydia: 94-100% cure versus 79-87% with azithromycin (adjusted OR 0.43,95% CI 0.21-0.91, p=0.0274) 1
• FDA-approved delayed-release formulation (200 mg once daily for 7 days) achieves 95.5% cure with better tolerability—nausea 13% versus 21%, vomiting 8% versus 12% 1

Both regimens are equally effective for genital infections based on meta-analyses of 12 randomized trials, so choose based on compliance likelihood and cost. 1, 2

---

Alternative Regimens (When First-Line Agents Cannot Be Used)

Use these only when azithromycin and doxycycline are contraindicated or not tolerated 1:

• Erythromycin base 500 mg orally four times daily for 7 days 1, 4
• Erythromycin ethylsuccinate 800 mg orally four times daily for 7 days 1, 4
• Ofloxacin 300 mg orally twice daily for 7 days 1
• Levofloxacin 500 mg orally once daily for 7 days (88-94% efficacy versus 97-98% for first-line agents; lacks clinical trial validation for chlamydia) 1

Caution: Erythromycin causes frequent gastrointestinal side effects leading to poor compliance, making it less desirable 1, 2. Fluoroquinolones offer no compliance advantage over doxycycline (both require 7 days) and are more expensive without superior efficacy 1.

---

Treatment During Pregnancy

Azithromycin 1 g orally as a single dose is the preferred treatment during pregnancy. 1

Alternative Options for Pregnant Patients

• Amoxicillin 500 mg orally three times daily for 7 days 1, 2
• Erythromycin base 500 mg orally four times daily for 7 days (if azithromycin cannot be tolerated) 1, 4
• Erythromycin base 250 mg orally four times daily for 14 days 1
• Erythromycin ethylsuccinate 800 mg orally four times daily for 7 days 1, 4
• Erythromycin ethylsuccinate 400 mg orally four times daily for 14 days 1

Absolute Contraindications in Pregnancy

• Doxycycline 1, 2
• All fluoroquinolones (ofloxacin, levofloxacin) 1
• Erythromycin estolate (causes drug-related hepatotoxicity) 1, 4

Mandatory Follow-Up in Pregnancy

• Test-of-cure is required 3-4 weeks after completing therapy (unlike non-pregnant patients) 1
• Culture is preferred when available; if using NAAT, wait at least 3-4 weeks to avoid false-positives from residual DNA 1
• Rationale: Alternative regimens have lower efficacy and higher non-compliance rates due to gastrointestinal side effects 1

---

Pediatric and Neonatal Treatment

Children ≥8 Years Weighing >45 kg

• Azithromycin 1 g orally as a single dose, OR
• Doxycycline 100 mg orally twice daily for 7 days 1

Children <45 kg

• Erythromycin base or ethylsuccinate 50 mg/kg/day orally divided into four doses for 14 days 1, 4

Neonates with Chlamydial Conjunctivitis or Pneumonia (Ages 1-3 Months)

• Erythromycin base or ethylsuccinate 50 mg/kg/day orally divided into four doses for 14 days 1, 4
• Effectiveness approximately 80%; a second course may be needed 1
• Alternative: Azithromycin suspension 20 mg/kg/day orally once daily for 3 days 1

Diagnostic caution: Do not use non-culture tests (EIA, DFA) in children due to false-positive results from cross-reaction with other organisms 1.

---

Sexual Activity Restrictions and Partner Management

Patient Instructions

• Abstain from all sexual intercourse for 7 days after initiating treatment, regardless of regimen 1, 3
• Continue abstinence until all sex partners have completed treatment 1, 3

Partner Management Protocol

• All sex partners from the previous 60 days must be evaluated, tested, and empirically treated, even if asymptomatic 1, 3
• If last sexual contact was >60 days before diagnosis, the most recent partner must still be treated 1, 3
• Treat partners empirically before test results are available—delaying treatment increases complications, transmission, and loss to follow-up 1
• Failing to treat partners leads to reinfection in up to 20% of cases 1

---

Concurrent Gonorrhea Management

• If gonorrhea is confirmed or prevalence exceeds 5% in the population, treat both infections concurrently with ceftriaxone 250 mg IM single dose PLUS azithromycin 1 g orally single dose 1, 3
• Coinfection rates range from 20-40% in many populations 1, 3
• In high-prevalence settings (e.g., STD clinics), presumptive treatment for both infections is appropriate even without testing 1, 3

---

Follow-Up and Retesting Strategy

Test-of-Cure (NOT Recommended in Most Cases)

• Do NOT perform test-of-cure in non-pregnant patients treated with recommended regimens who are asymptomatic, as cure rates exceed 97% 1, 3, 2
• Test-of-cure is indicated only when:
  • Therapeutic compliance is questionable
  • Symptoms persist after treatment
  • Reinfection is suspected 1, 2
• Do NOT test before 3 weeks post-treatment—NAAT can yield false-positives from dead organisms 1

Mandatory Reinfection Screening

• All women must be retested approximately 3 months after treatment to screen for reinfection, regardless of whether partners were reportedly treated 1, 3
• Reinfection rates reach up to 39% in some adolescent populations 1
• Repeat infections carry elevated risk for pelvic inflammatory disease and complications compared to initial infection 1, 3
• Men may also benefit from retesting at 3 months, though evidence is more limited 1

---

Additional STI Testing at Initial Visit

• Test for gonorrhea, syphilis, and HIV at the time of chlamydia diagnosis 1
• Consider HPV vaccination referral if age-appropriate 1

---

Critical Pitfalls to Avoid

• Do NOT wait for test results if compliance with return visit is uncertain—treat presumptively in high-prevalence populations 1, 3
• Do NOT perform test-of-cure before 3 weeks post-treatment due to false-positive NAAT results 1
• Do NOT assume partners were treated—directly verify or use expedited partner therapy 1, 3
• Do NOT use erythromycin as first-line treatment due to poor compliance from gastrointestinal side effects 1, 2
• Do NOT retreat based on symptoms alone without documenting objective signs of urethral inflammation (≥5 WBC per high-power field) 1
• Do NOT use fluoroquinolones or tetracyclines in pregnancy due to teratogenic risk 1